Nick Train lifts his ‘skin’ in Finsbury Growth with £1m of share purchases
Flurry of share deals sees fund manager raise his stake in Finsbury Growth & Income to 2.3%.
Investment company news brought to you by Citywire Financial Publishers Limited and Quoted Data by Marten & Co.
Flurry of share deals sees fund manager raise his stake in Finsbury Growth & Income to 2.3%.
Hopes of Andrew Craig to launch a life sciences fund on the stock exchange founder in difficult market conditions. Attention turns to see if infrastructure fund AT85 can succeed with its float next month.
Double release of first quarter and annual results from Jupiter's growth capital fund fail to impress, showing 46% slump in asset value last year and prospect of more writedowns to come.
The once top-performing US investment trust lags the S&P 500 index since launch after a painful two-year crash but its managers want time for their strategy to revive.
HydrogenOne Capital Growth, the only specialist hydrogen investment trust launched so far, has had a rocky time but developments in the energy sector suggest other funds may follow.
Two successful clinical trials and a takeover of one portfolio company by AstraZeneca brought a difficult 2022 to a happy conclusion leaving RTW managers cautiously optimistic.
Civitas Social Housing distances itself from suspended Home Reit, saying its rents continue to grow despite tenant My Space failing to pay rents in recent months.
Tufton Oceanic Assets (SHIP) hopes to benefit from China's reopening and increased shipping to refineries in Asia and the Middle East to bounce back from a drop in asset value at the end of last year.
Investors in Octopus Renewables Infrastructure and Greencoat UK Wind have enjoyed a large boost to income as soaring gas and electricity bills spark a rush for renewables.
Floating rate debt fund lifts its quarterly dividend by 1p to 2.5p per share, more than double the payout two years ago, as interest rates take the portfolio's underlying yield to 13%.
Portfolio manager Simon Barnard rules out changing his quality growth style after a punishing 2022, but premium tonic maker Fevertree may be up for review.
Smithson fund manager Simon Barnard rules out changing his quality growth style after a punishing 2022. Premium tonic maker Fevertree may be up for review, though.
Developed by Moore-Wilson